TLC Standards
      

TLC is pleased to announce the launch of Peptide Chemistry Laboratory

In order to meet the growing need and demand in the Pharmaceutical Industry, TLC is proud to announce the addition of Peptides and related compounds synthesis to our existing line of products.

A new Laboratory has been established with experienced scientists and equipment solely dedicated to synthesizing the reference standards for therapeutic peptide drugs.




CPHI China
June 20 - 22,2017 | Shanghai New Int'l Centre (SNIEC), Shanghai, China


Come meet our sales and technical team at booth #T2C01​ to discuss how TLC can support and improve on your present and future Reference Standards needs.



In order to accommodate the company’s continued growth, TLC is proud to announce that we will be relocating our Headquarters on February 22nd to new and larger facilities.
Our new address is:
Unit 7&8, 305 Industrial Parkway South, Aurora, Ontario, L4G 6X7
Phone: (905)-727-8998
Fax: (905)-727-5995
Our clients can trust that TLC will continue to thrive to surpass the level of quality and service that our reputation has been built on.




TLC is pleased to announce the launch of our new website (www.tlcstandards.com) following a change in the company’s name.
In order to better reflect the nature of our business, with our main focus being the supply of reference standards to the pharmaceutical industry, and to continue to offer a high level of service, as of March 1st 2015, TLC will be changing its name from TLC PharmaChem Inc. to TLC Pharmaceutical Standards Ltd. All previous operations as well as senior management will not be impacted and remain unchanged.
TLC’s success and growth over the past several years has been in direct correlation to our valued client’s trust and loyalty. We pride ourselves in offering our customers products with an uncompromised level of quality while maintaining a high level of service, competitive pricing and aggressive timing.
Thank you and we look forward to working with you for a long time to come.




TLC Standards and GLSyntech Enter into an Agreement With Pfizer to Obtain and Supply Pfizer Research Compounds

TLC Standards and GLSyntech, recently entered into an agreement with Pfizer to obtain Pfizer research compounds, which both TLC Standards and GLSyntech, in turn, supply to investigators for use in their preclinical research studies. These compounds are highly-characterized chemical structures that may be used by investigators as research tools in preclinical research studies examining a number of parameters, including drug impurity profiling, metabolism, degradation, pharmacokinetics and pharmacology.
GLST/TLC, a Joint Venture between GLSyntech and TLC Standards, is a world leader in developing and synthesizing pharmaceutical reference compounds for use as research tools with more than ten years of successful experience in this field.
"We are very excited to have this opportunity to work with Pfizer to make these Pfizer compounds available to researchers," said Dr. Bing Yu, General Manager of GLSyntech.